JPWO2022102737A1 - - Google Patents

Info

Publication number
JPWO2022102737A1
JPWO2022102737A1 JP2022562195A JP2022562195A JPWO2022102737A1 JP WO2022102737 A1 JPWO2022102737 A1 JP WO2022102737A1 JP 2022562195 A JP2022562195 A JP 2022562195A JP 2022562195 A JP2022562195 A JP 2022562195A JP WO2022102737 A1 JPWO2022102737 A1 JP WO2022102737A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562195A
Other languages
Japanese (ja)
Other versions
JPWO2022102737A5 (cg-RX-API-DMAC7.html
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPWO2022102737(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of JPWO2022102737A1 publication Critical patent/JPWO2022102737A1/ja
Publication of JPWO2022102737A5 publication Critical patent/JPWO2022102737A5/ja
Priority to JP2025002313A priority Critical patent/JP2025061070A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022562195A 2020-11-12 2021-11-12 Pending JPWO2022102737A1 (cg-RX-API-DMAC7.html)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002313A JP2025061070A (ja) 2020-11-12 2025-01-07 エダラボン経口投与用医薬組成物およびその投与方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020188514 2020-11-12
PCT/JP2021/041673 WO2022102737A1 (ja) 2020-11-12 2021-11-12 エダラボン経口投与用医薬組成物およびその投与方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002313A Division JP2025061070A (ja) 2020-11-12 2025-01-07 エダラボン経口投与用医薬組成物およびその投与方法

Publications (2)

Publication Number Publication Date
JPWO2022102737A1 true JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2022-05-19
JPWO2022102737A5 JPWO2022102737A5 (cg-RX-API-DMAC7.html) 2023-07-12

Family

ID=81602356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562195A Pending JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2020-11-12 2021-11-12
JP2025002313A Pending JP2025061070A (ja) 2020-11-12 2025-01-07 エダラボン経口投与用医薬組成物およびその投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002313A Pending JP2025061070A (ja) 2020-11-12 2025-01-07 エダラボン経口投与用医薬組成物およびその投与方法

Country Status (11)

Country Link
US (2) US11911366B2 (cg-RX-API-DMAC7.html)
EP (1) EP4245303A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2022102737A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230098267A (cg-RX-API-DMAC7.html)
CN (1) CN116761601A (cg-RX-API-DMAC7.html)
AR (1) AR124062A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021380319B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198014A1 (cg-RX-API-DMAC7.html)
IL (1) IL302533A (cg-RX-API-DMAC7.html)
TW (1) TW202228678A (cg-RX-API-DMAC7.html)
WO (1) WO2022102737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024036261A2 (en) * 2022-08-10 2024-02-15 Kpr U.S., Llc Occlusion detection system and method for a flow control apparatus
EP4559463A1 (en) * 2023-11-23 2025-05-28 Ferrer Internacional, S.A. Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091036A1 (ja) * 2018-11-02 2020-05-07 田辺三菱製薬株式会社 経口投与用エダラボン懸濁剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
CN109125261B (zh) * 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
EP3785703A1 (en) * 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
JP7012792B2 (ja) 2020-08-06 2022-01-28 株式会社 ディー・エヌ・エー 動画を配信するためのシステム、方法、及びプログラム
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091036A1 (ja) * 2018-11-02 2020-05-07 田辺三菱製薬株式会社 経口投与用エダラボン懸濁剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HYUNG, S., ET AL.: "Identification of the primary determining factor(s) governing the oral absorption of edaravone in ra", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 123, JPN6021050111, 2018, pages 312 - 320, XP085463093, ISSN: 0005303857, DOI: 10.1016/j.ejps.2018.07.052 *
LI, Q., ET AL.: "Gastric retention pellets of edaravone with enhanced oral bioavailability: Absorption mechanism, dev", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 119, JPN6021050113, 2018, pages 62 - 69, XP055929403, ISSN: 0005303858, DOI: 10.1016/j.ejps.2018.04.002 *
QURESHI, I., ET AL.: "A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV-0223) and Oral Tablet Form", CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, vol. 9, no. 4, JPN6021050114, 2019, pages 476 - 485, ISSN: 0005303859 *
TAKEI, K., ET AL.: "Radicava (edaravone) for amyotrophic lateral sclerosis: new formulation and its development plan", AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, vol. Vol.19(Supple. S1), JPN6021050110, 2018, pages 272 - 13, ISSN: 0005434760 *

Also Published As

Publication number Publication date
US12478611B2 (en) 2025-11-25
TW202228678A (zh) 2022-08-01
US20220142982A1 (en) 2022-05-12
AU2021380319B2 (en) 2025-03-20
IL302533A (en) 2023-07-01
US11911366B2 (en) 2024-02-27
CN116761601A (zh) 2023-09-15
AU2025203773A1 (en) 2025-06-12
WO2022102737A1 (ja) 2022-05-19
KR20230098267A (ko) 2023-07-03
US20240173297A1 (en) 2024-05-30
AR124062A1 (es) 2023-02-08
EP4245303A4 (en) 2024-10-09
CA3198014A1 (en) 2022-05-19
EP4245303A1 (en) 2023-09-20
JP2025061070A (ja) 2025-04-10
AU2021380319A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
CN306151973S (zh) 台灯(龙头)
CN306043723S (zh) 手提包
CN306054435S (zh) 香薰机(镂空型)
BR102021012230A2 (cg-RX-API-DMAC7.html)
CN305919065S (zh) 包装袋(太子佬鸡精调味料1)
CN305900920S (zh) 落地三角折叠架
CN305870510S (zh) 弹力跳床(四折叠)
CN305856681S (zh) 体育场用座椅
CN305944193S (zh) 餐具(小鱼款餐叉餐勺)
CN305866173S (zh) 玻璃胶瓶(大友)
CN305941800S (zh) 鞋面(3216)
CN305920593S (zh) 蓝牙音箱(nr-2027)
CN305861322S (zh) 儿童挖掘机
CN305858501S (zh) 瓶塞(我的球包“创意琉璃球包”)
CN305898630S (zh) 筒灯
CN305845736S (zh) 内衣(qy1137)
CN305827192S (zh) 戒指(5)
CN305840993S (zh) 裤架(二)
CN305851902S (zh) 定位终端(gt010)
CN305945901S (zh) 壁挂式动态人脸识别终端(tg02)
CN305838338S (zh) 拖布池(143-1)
CN305853681S (zh) 电暖器(ch-3300m-20)
CN305854451S (zh) 木门(简奢雅韵)
CN305847072S (zh) 置物架
CN305868018S (zh) 挂钩(摩托车多功能拓展)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250107